Sunitinib and Capecitabine for First Line Colon Cancer

NCT ID: NCT00961571

Last Updated: 2025-02-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2011-03-31

Brief Summary

This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve progression-free survival in colorectal cancer.

All patients will take two medicines (Sunitinib and Capecitabine) by mouth every day until their cancer gets worse.

Detailed Description

This is a single-center, open-label, one-arm study. Patients will be stratified by prior adjuvant therapy and ECOG performance status at study entry.

In this study, we propose to obtain PET scans at baseline, 2 weeks, 8 weeks and 24 weeks from the initiation of treatment. Response at 2 weeks, 8 weeks and 24 weeks will be correlated to progression-free survival, overall survival and response according to RECIST criteria.

We will collect plasma and urine samples from enrolled patients before and four weeks after sunitinib treatment. The samples will be analyzed and results correlated with patient clinical outcomes in order to explore the underlying mechanism of sunitinib induced hypertension.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

sunitinib and cepecitabine

Administration of sunitinib and capecitabine

Group Type: EXPERIMENTAL

sunitinib and capecitabine

Intervention Type: DRUG

Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily

Interventions

sunitinib and capecitabine

Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily

Intervention Type: DRUG

Other Intervention Names

Sunitinib, NSC 736511, Sutent; Capecitabine, Xeloda

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed, newly diagnosed metastatic colorectal cancer
• Measurable or evaluable disease in which surgical resection with curative intent is not possible
• No adjuvant chemotherapy within 6 months of enrollment
• No prior sunitinib or other receptor tyrosine kinase inhibitors
• 18 years of age or greater
• Anticipated survival of at least 6 months
• Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight
• Normal organ and marrow function
• Must agree to avoid pregnancy or fathering a child through out study participation
• Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

• Chemotherapy or radiotherapy within 6 months of enrollment
• Receiving any other investigational agents
• Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis
• Not able to ingest oral medications with normal absorption from the GI tract
• Uncontrolled hypertension
• History of severe/unstable angina, heart attack, congestive heart failure, transient ischemic attack, or stroke within 6 months of enrollment
• Cardiac dysrhythmias
• History of clinically significant bleeding within the past 6 months, including gross hemoptysis or hematuria, or underlying coagulopathy
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study enrollment
• Current treatment with therapeutic doses of coumadin
• Concurrent malignancy other than colorectal cancer
• Known dihydropyrimidine dehydrogenase deficiency
• Uncontrolled intercurrent illness including ongoing or active infection or psychiatric illness that would limit compliance with study requirements.
• Pregnant and nursing women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

Georgetown University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aiwu Ruth He, MD

Role: PRINCIPAL_INVESTIGATOR

Georgetown University

Locations

Lombardi Cancer Center at Georgetown University

Washington D.C., District of Columbia, United States

Countries

United States

Other Identifiers

2008-308

Identifier Type: OTHER

Identifier Source: secondary_id

GA61822D

Identifier Type: -

Identifier Source: org_study_id